Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00275262 · OUTCOME

Mean Change From Baseline in TREC Per 100,000 CD8+ Cells to Final Visit in Patients Treated With LAD (11.25 mg) or Placebo After Transplant

A Study to Evaluate the Ability of Lupron Depot to Enhance Immune Function Following Bone Marrow Transplantation · Source last updated 2010-05-06

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
TREC /100,000 CD8+ cells
Interval / dispersion
Standard Deviation
Time frame
Pretransplant and posttransplant (Month 12)

What was measured

CD8+ cells are a type of T cell. T cells are produced in the thymus and thymic function can be determined by TREC. By counting the number of TRECs present (only 1 copy per cell) within a population of CD8+ cells, an assessment of T cell recovery and immune response is obtained. Mayo Medical Clinic. http://www.mayomedicallaboratories.com/test-catalog/Clinical+and+Interpretive/87959. Accessed 17 MARCH 2010 The change from baseline is defined as posttransplant TREC/100,000 CD8+ cells minus pretransplant TREC /100,000 CD8+ cells.

Analysis population: Eight subjects from the LAD-treated arm and 5 subjects from the placebo-treated arm were assessed for TREC per 100,000 CD8+ cells. These subjects received 3 doses of LAD or placebo, KLH vaccination, and had a blood collection suitable for analysis for primary endpoint although not all subjects completed the entire study.

Groups in this outcome

Leuprolide Acetate Depot (LAD) 11.25 mg 3 Month

Patients received 1 injection of LAD 11.25 mg every 3 months for a total treatment period of 9 months.

Placebo

Patients received 1 injection of placebo every 3 months for a total treatment period of 9 months.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Leuprolide Acetate Depot (LAD) 11.25 mg 3 Month9
Placebo7

Reported measurements

Baseline mean for TREC per 100,000 CD8+ cells
Values in TREC /100,000 CD8+ cells · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Leuprolide Acetate Depot (LAD) 11.25 mg 3 Month181.673209.7599Not reportedNot reportedNot reported
Placebo364.414280.3465Not reportedNot reportedNot reported
Mean change in TREC from baseline to final visit
Values in TREC /100,000 CD8+ cells · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Leuprolide Acetate Depot (LAD) 11.25 mg 3 Month-10.811343.061Not reportedNot reportedNot reported
Placebo-184.084282.405Not reportedNot reportedNot reported

Source statistical analyses

Group order, estimate direction, methods and comments are retained. No treatment ranking is inferred.

  1. group Description
    The final on treatment values were included in the analysis.
    group Ids
    1. OG000
    2. OG001
    non Inferiority Type
    SUPERIORITY_OR_OTHER
    p Value
    0.299
    statistical Comment
    The statistical method used for a 1-way ANOVA between treatment groups.
    statistical Method
    ANOVA
    tested Non Inferiority
    false
Complete source fields
analyses
  1. group Description
    The final on treatment values were included in the analysis.
    group Ids
    1. OG000
    2. OG001
    non Inferiority Type
    SUPERIORITY_OR_OTHER
    p Value
    0.299
    statistical Comment
    The statistical method used for a 1-way ANOVA between treatment groups.
    statistical Method
    ANOVA
    tested Non Inferiority
    false
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        209.7599
        value
        181.673
      2. group Id
        OG001
        spread
        280.3465
        value
        364.414
    title
    Baseline mean for TREC per 100,000 CD8+ cells
  2. categories
    1. measurements
      1. group Id
        OG000
        spread
        343.061
        value
        -10.811
      2. group Id
        OG001
        spread
        282.405
        value
        -184.084
    title
    Mean change in TREC from baseline to final visit
denoms
  1. counts
    1. group Id
      OG000
      value
      9
    2. group Id
      OG001
      value
      7
    units
    Participants
description
CD8+ cells are a type of T cell. T cells are produced in the thymus and thymic function can be determined by TREC. By counting the number of TRECs present (only 1 copy per cell) within a population of CD8+ cells, an assessment of T cell recovery and immune response is obtained. Mayo Medical Clinic. http://www.mayomedicallaboratories.com/test-catalog/Clinical+and+Interpretive/87959. Accessed 17 MARCH 2010 The change from baseline is defined as posttransplant TREC/100,000 CD8+ cells minus pretransplant TREC /100,000 CD8+ cells.
dispersion Type
Standard Deviation
groups
  1. description
    Patients received 1 injection of LAD 11.25 mg every 3 months for a total treatment period of 9 months.
    id
    OG000
    title
    Leuprolide Acetate Depot (LAD) 11.25 mg 3 Month
  2. description
    Patients received 1 injection of placebo every 3 months for a total treatment period of 9 months.
    id
    OG001
    title
    Placebo
param Type
MEAN
population Description
Eight subjects from the LAD-treated arm and 5 subjects from the placebo-treated arm were assessed for TREC per 100,000 CD8+ cells. These subjects received 3 doses of LAD or placebo, KLH vaccination, and had a blood collection suitable for analysis for primary endpoint although not all subjects completed the entire study.
reporting Status
POSTED
time Frame
Pretransplant and posttransplant (Month 12)
title
Mean Change From Baseline in TREC Per 100,000 CD8+ Cells to Final Visit in Patients Treated With LAD (11.25 mg) or Placebo After Transplant
type
SECONDARY
unit Of Measure
TREC /100,000 CD8+ cells

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice